Chu Jianfeng

Dr. Chu Jianfeng


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
YCYing Cheng
Ying Cheng
ASAling Shen
Aling Shen
XWXiangyan Wu
Xiangyan Wu
ZSZhiqing Shen
Zhiqing Shen
XCXiaoping Chen
Xiaoping Chen
JPJun Peng
Jun Peng
Qingda granule (QDG), simplified from Qingxuan Jiangya Decoction, is a well-known traditional Chinese medicine formula that has been used for decades to treat hypertension. However, the cardioprotective effects of QDG on Ang II-induced hypertension remain unknown. This study aimed to investigate the effects of QDG on hypertension-induced cardiac hypertrophy and apoptosis, as well as explore its underlying mechanisms. Mice were infused with Ang II (500 ng/kg/min) or saline solution as control, then administered oral QDG (1.145 g/kg/day) or saline for two weeks. QDG treatment attenuated the elevation in blood pressure caused by Ang II, as well as the decreased left ventricle ejection fractions and fractional shortening. Moreover, QDG treatment significantly alleviated the Ang II-induced elevation of the ratio of heart weight to tibia length, as well as cardiac injury, hypertrophy, and apoptosis. In cultured H9C2 cells stimulated with Ang II, QDG partially reversed the increase in cell surface area and number of apoptotic cells, up-regulation of hypertrophy markers ANP and BNP, and activation of caspases-9 and -3. QDG also partially reversed Ang II-induced accumulation of reactive oxygen species (ROS), depolarization of the mitochondrial membrane, release of cytochrome C, up-regulation of Bax, and decrease in levels of p-PI3K, p-AKT, and Bcl-2. These results suggest that QDG can significantly attenuate Ang II-induced hypertension, cardiac hypertrophy and apoptosis, and it may exert these effects in part by suppressing ROS production and activating the PI3K/AKT signaling pathway.

12 August 2021 in Aging Clinical and Experimental Research
Verified
Journal Article
Closed access
PDF file
QMQiuyan Meng
Qiuyan Meng
HYHuiru Yin
Huiru Yin
SWShuo Wang
Shuo Wang
BSBinghan Shang
Binghan Shang
XMXiangfei Meng
Xiangfei Meng
LCLi Chen
Li Chen

4 January 2024 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
QCQiaoyan Cai
Qiaoyan Cai
CZChunyu Zhao
Chunyu Zhao
YXYao yao Xu
Yao yao Xu
HLHaowei Lin
Haowei Lin
BJBeibei Jia
Beibei Jia
JPJun Peng
Jun Peng

14 October 2015 in Molecules
Verified
Journal Article
Open access
PDF file
DCDaxin Chen
Daxin Chen
SLShan Lin
Shan Lin
WXWen Xu
Wen Xu
MHMing-Qing Huang
Ming-Qing Huang
CJChu Jianfeng
Chu Jianfeng
JPJun Peng
Jun Peng
Shexiang Tongxin dropping pill (STP) is a traditional Chinese medicine formula that consists of total saponins of ginseng, synthetic Calculus bovis, bear gall, Venenum bufonis, borneol and Salvia miltiorrhiza. STP has been widely used in China and Southeast Asia for the treatment of cardiovascular diseases. In this study, a qualitative analytical method using high performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry was developed for identification of the major constituents in STP. Based on the retention time and MS spectra, 41 components were identified by comparison with reference compounds and literature data. Moreover, using ultra-performance liquid chromatography coupled with triple-quadrupole tandem mass spectrometry in multiple-reaction monitoring mode, we quantified 13 of the identified constituents (ginsenoside Rg1, ginsenoside Rk3, cinobufagin, arenobufagin, bufalin, resibufogenin, tanshinone IIA, taurine, tauroursodeoxycholic acid, taurocholic acid, cholic acid, deoxycholic acid, and chenodeoxycholic acid). These results suggest that this new approach is applicable for the routine analysis and quality control of STP products and provides fundamental data for further in vivo pharmacokinetical studies.

1 June 2021 in Complementary Therapies in Medicine
Verified
Journal Article
Open access
CWCong Wang
Cong Wang
GLGuichen Li
Guichen Li
LZLufang Zheng
Lufang Zheng
XMXiangfei Meng
Xiangfei Meng
QMQiuyan Meng
Qiuyan Meng
LCLi Chen
Li Chen
Music interventions have several benefits for sleep quality. However, the effects of music interventions on sleep quality in older adults are controversial. To summarize and evaluate the efficacy of music interventions on sleep quality in older adults. The Cochrane Library, Embase, PubMed, Web of Science and Chinese National Knowledge Infrastructure (CNKI) were systematically retrieved until June 2020, updated on March 13, 2021. Both experimental and quasi-experimental studies were included if they evaluated the efficacy of music interventions on sleep outcomes in older adults. The methodological quality was assessed by the Cochrane RoB 2.0 and ROBINS-I Tool. The random effects models and effect measure (MD) were adopted, and sensitivity analysis by omitting each study was conducted to explore the source of heterogeneity. A total of 489 participants from 9 studies met the inclusion criteria. 6 studies were included in meta-analysis and sensitivity analysis, and 3 studies were included in the qualitative analysis. Main concerns about risk of bias were lack of blinding participants and investigators, and confounding factors might exist in non-RCTs. The Post-hoc meta-analysis indicated that music interventions might have a positive effect on sleep quality [MD = -2.64, 95 % CI (-3.76, -1.53), p < 0.001; I2 = 75.0 %]. Only one study evaluated adverse events and reported zero discomfort. The results indicated that music interventions might be beneficial for improving sleep quality, especially in sleep latency, sleep duration, sleep efficiency and sleep of daytime dysfunction in elderly individuals.

18 August 2021 in Immunity, Inflammation and Disease
Verified
Journal Article
Open access
PDF file
ZZZhengchuan Zhu
Zhengchuan Zhu
MWMiaoran Wang
Miaoran Wang
WLWei Lin
Wei Lin
QCQiaoyan Cai
Qiaoyan Cai
LZLing Zhang
Ling Zhang
KCKeji Chen
Keji Chen
Aims: To explore the correlation between cardiac‐related comorbidities, cardiac biomarkers, acute myocardial injury, and severity level, outcomes in COVID‐19 patients.Method: Pubmed, Web of Science, Embase, CNKI, VIP, Wanfang, Cochrane Library databases, medRxiv, and Sinomed were reviewed systemically. Various types of clinical research reporting cardiac‐related comorbidities, cardiac biomarkers including lactate dehydrogenase (LDH), troponin I (TnI), high sensitivity troponin I (hs‐TnI), creatine kinase (CK), creatine kinase–MB (CK‐MB), myoglobin (Myo), N‐terminal pro‐b‐type natriuretic peptide (NT‐proBNP) and acute cardiac injury grouped by severity of COVID‐19 were included. Outcome measures were events and total sample size for comorbidities, acute cardiac injury, and laboratory parameters of these biomarkers. The study was performed with Stata version 15.1.Results: Seventy studies, with a total of 15,354 cases were identified. The results showed that COVID‐19's severity was related to cardiovascular disease. Similar odds ratios (ORs) were achieved in hypertension except for severe versus critical group (OR = 1.406; 95% CI, 0.942–2.097; p = .095). The relative risk (RR) of acute cardiac injury is 7.01 (95% CI, 5.64–8.71) in non‐survivor cases. When compared with the different severity of cardiac biomarkers, the pool OR of CK, CK‐MB, TnI, Myo and LDH were 2.683 (95% CI, 0.83–8.671; p = .106; I2 = 0%), 2.263 (95% CI, 0.939–5.457; p = .069), 1.242 (95% CI, 0.628–2.457; p = .534), 1.756 (95% CI, 0.608–5.071; p = .298; I2 = 42.3%), 1.387 (95% CI, 0.707–2.721; p = .341; I2 = 0%) in the critical versus severe group, whose trends were not similar to other groups. The standard mean differences (SMD) of CK and TnI in the critical versus severe group were 0.09 (95% CI, −0.33 to 0.50; p = .685; I2 = 65.2%), 0.478 (95% CI, −0.183 to 1.138; p = .156; I2 = 76.7%), which means no difference was observed in the serum level of these indicators.Conclusion: Most of the findings clearly indicate that hypertension, cardiovascular disease, acute cardiac injury, and related laboratory indicators are associated with the severity of COVID‐19. What is now needed are cross‐national prospectively designed observational or clinical trials that will help improve the certainty of the available evidence and treatment decisions for patients.